SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 27, 2001
SCICLONE PHARMACEUTICALS, INC.
| California (State or other jurisdiction of incorporation) | 0-19825 (Commission File No.) | 94-3116852 (IRS Employer Identification No.) |
901 Mariner’s Island Boulevard, Suite 205
San Mateo, California 94404
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:(650) 358-3456
| Item 5. Other Events. | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| Exhibit 3.1 | ||||||||
Item 5. Other Events.
On July 27, 2001, the Board of Directors of SciClone Pharmaceuticals, Inc. (the “Company”) amended and restated Article II, Section 2.2 and added new Sections 2.14, 2.15 and 2.16 to the Bylaws of the Company to set forth specific provisions regulating the conduct of stockholders’ meetings and the business that may be transacted at annual meetings. In addition, the Board of Directors added a new Article III, Section 3.12 to set forth specific provisions regulating the nomination of candidates for the Board of Directors.
Item 7. Financial Statements and Exhibits.
The Amended and Restated Bylaws of the Company are attached hereto as Exhibit 3(ii).1.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SCICLONE PHARMACEUTICALS, INC. | ||
| | ||
| Date: September 17, 2001 | By: | /s/ Richard A. Waldron |
| Richard A. Waldron Chief Financial Officer and Secretary | ||
3
EXHIBIT INDEX
| Exhibit | Description | |||||
| 3(ii).1 | Amended and Restated Bylaws of SciClone Pharmaceuticals, Inc. |
4
